Outcomes of basiliximab <i>vs</i> alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study
In this propensity score-matched analysis, alemtuzumab induction was associated with lower graft function at 12 months and higher risks of viral infection, post-transplant malignancy, and graft loss compared with basiliximab. These findings highlight the need for further studies to confirm the long-term safety and effectiveness of alemtuzumab in kidney transplantation.
Authors
- Marcus Lowe (ORCID: https://orcid.org/0000-0002-0799-1674)
- Kay Poulton (ORCID: https://orcid.org/0000-0002-5608-8107)
- Chukwuma Austin Chukwu
- Philip A Kalra
- Titus Augustine
- Anirudh Rao
Institutions
- University of Liverpool (GB)
- Aintree University Hospitals NHS Foundation Trust (GB)
- Manchester Academic Health Science Centre (GB)
- Salford Royal NHS Foundation Trust (GB)
- Manchester Royal Infirmary (GB)
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
- Salford Royal Hospital (GB)
Publication Details
- Journal
- World Journal of Transplantation
- Published
- 2026-01-14
- DOI
- https://doi.org/10.5500/wjt.v16.i1.111959
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00